Since capex for biotech firms are highly volatile, especially in pre-revenue/pre-commercialization phases, I am not certain a formula is the best way to think about it. Usually, management/ER have disclosure about capex for the next few years than can be helpful.

 
Most Helpful

I do not cover biotech or have any interest in biotech companies but I would assume that you will have to do this on a company by company basis rather than derive some kind of formula that can be applied across multiple firms. If it were me, I would look through the established players who have drugs in their pipeline or in development that are similar to your target and use that as a basis. Alternatively, I'm assuming your company has raised capital or has a history of capital raises. I would also assume your company has published the number of employees working for it. Thus, I would model a level of G&A spend for these employees (make some type of assumption between R&D staff, admin, mgt, sales and marketing team; come up with a model for these costs based on average salaries for similar companies, can use glassdoor for reference points), and then I would assume that essentially all other capital the company has raised is devoted to capex. When I say capex, I don't mean capex in a traditional manufacturing capacity or relative to the balance sheet, I mean in terms of total investment (R&D, advertising, traditional capital investment).

If your question is more so related to more traditional balance sheet investments specifically, I would again look at comps and search their PP&E/operating lease disclosures for potential reference points. You could also look through whatever city/town they have a presence in, figure out local commercial real estate costs, figure out what type of equipment they likely need to operate and the ASPs of whatever units are needed. That should give you an all-in type cost, then put together a depreciation schedule and assume that future capex matches off that depreciation (in essence no growth investment, purely maintenance spend). I would think that the company isn't going to make substantial PP&E growth investments until it begins generating revenue and/or showing promise in its drug pipeline. 

Tough to give a more specific answer based on the information provided (egregious use of the word assume in my response as a result), just throwing out some ideas that would be my initial thoughts if I had the same task. 

 

Modi nulla voluptatem voluptatibus qui. Quod omnis vel aut in voluptatum. Quaerat sit velit aut pariatur.

Career Advancement Opportunities

April 2024 Hedge Fund

  • Point72 98.9%
  • D.E. Shaw 97.9%
  • Citadel Investment Group 96.8%
  • Magnetar Capital 95.8%
  • AQR Capital Management 94.7%

Overall Employee Satisfaction

April 2024 Hedge Fund

  • Magnetar Capital 98.9%
  • D.E. Shaw 97.8%
  • Blackstone Group 96.8%
  • Two Sigma Investments 95.7%
  • Citadel Investment Group 94.6%

Professional Growth Opportunities

April 2024 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 97.9%
  • D.E. Shaw 96.9%
  • Magnetar Capital 95.8%
  • Citadel Investment Group 94.8%

Total Avg Compensation

April 2024 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (23) $474
  • Director/MD (12) $423
  • NA (6) $322
  • 3rd+ Year Associate (24) $287
  • Manager (4) $282
  • Engineer/Quant (71) $274
  • 2nd Year Associate (30) $251
  • 1st Year Associate (73) $190
  • Analysts (225) $179
  • Intern/Summer Associate (22) $131
  • Junior Trader (5) $102
  • Intern/Summer Analyst (250) $85
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
kanon's picture
kanon
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
numi's picture
numi
98.8
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”